Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma

Ralph Schwiebert, MBBS, Sharon Barrans, PhD, Jan Taylor, Andrew S Jack, Cathy H Burton

Blood (2015) 126 (23): 1437.

https://doi.org/10.1182/blood.V126.23.1437.1437

Published: 2015

Journal Articles

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

Niamh Appleby, Ruth Cullen, Dan Painter, Alexandra Smith, Eve Roman, Sharon Barrans, PhD, Sheila J.M. O'Connor, Catherine H Burton, Andrew S Jack, Roger G Owen, Reuben M Tooze, PhD FRCP

Blood (2015) 126 (23): 3924.

https://doi.org/10.1182/blood.V126.23.3924.3924

Published: 2015

Journal Articles

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

Catherine A. Cargo, Nicola Rowbotham, Paul A. Evans, Sharon L. Barrans, David T. Bowen, Simon Crouch, Andrew S. Jack

Blood (2015) 126 (21): 2362–2365.

https://doi.org/10.1182/blood-2015-08-663237

Published: 2015

Includes: Supplemental data

Journal Articles

The Emergence of Clonally Related Hodgkin Lymphoma Following B-Cell Malignancies Treated with Rituximab.

Catherine H Burton, MBBChir, MD, MRCP, FRCPath, Sheila J.M. zsnO'Connor, Roger G Owen, Andrew S Jack

Blood (2009) 114 (22): 3664.

https://doi.org/10.1182/blood.V114.22.3664.3664

Published: 2009

Journal Articles

Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease.

Fiona L Bennett, Surita Dalal, Andrew S Jack, Peter Hillmen, Andy C. Rawstron

Blood (2009) 114 (22): 59.

https://doi.org/10.1182/blood.V114.22.59.59

Published: 2009

Journal Articles

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

Andrew S. Jack, Sharon L. Barrans, Wendi Qian, Sally P. Stenning, Graham M. Mead

Blood (2009) 114 (2): 486–487.

https://doi.org/10.1182/blood-2009-04-214627

Published: 2009

Journal Articles

The Pattern of BCL6 Intron 1 Mutations in Healthy Individuals with BCL2;IgH Is Similar to That Seen in Lymphomas

Lisa J Worrillow, Rob Newton, Andrew S Jack

Blood (2008) 112 (11): 3800.

https://doi.org/10.1182/blood.V112.11.3800.3800

Published: 2008

Journal Articles

Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are Frequently Observed in Diffuse Large B-Cell Lymphoma

Maayke Boll, Sharon L Barrans, Charles S McManamy, Andrew S Jack

Blood (2008) 112 (11): 3761.

https://doi.org/10.1182/blood.V112.11.3761.3761

Published: 2008

Journal Articles

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

Blood (2008) 112 (11): 2618.

https://doi.org/10.1182/blood.V112.11.2618.2618

Published: 2008

Journal Articles

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

Andy C Rawstron, BSc, PhD, Darren J Newton, Ruth M. de Tute, Jane Shingles, Fiona L Bennett, Paul A.S. Evans, Sheila J.M. O’Connor, Andrew S Jack, Peter Hillmen

Blood (2008) 112 (11): 2076.

https://doi.org/10.1182/blood.V112.11.2076.2076

Published: 2008

Journal Articles

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Graham M. Mead, Sharon L. Barrans, Wendi Qian, Jan Walewski, John A. Radford, Max Wolf, Simon M. Clawson, Sally P. Stenning, Claire L. Yule, Andrew S. Jack

Blood (2008) 112 (6): 2248–2260.

https://doi.org/10.1182/blood-2008-03-145128

Published: 2008

Journal Articles

Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCL

Philip J. Brown, Sally L. Ashe, Ellen Leich, Christof Burek, Sharon Barrans, James A. Fenton, Andrew S. Jack, Karen Pulford, Andreas Rosenwald, Alison H. Banham

Blood (2008) 111 (5): 2816–2824.

https://doi.org/10.1182/blood-2007-09-115113

Published: 2008

Includes: Supplemental data

Journal Articles

Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.

Andy C. Rawstron, Fiona L. Bennet, Sheila J.M. O’Connor, Marwan Kwok, James A.L. Fenton, Marieth Plummer, Ruth M. de Tute, Roger G. Owen, Stephen J. Richards, Andrew S. Jack, Peter Hillmen

Blood (2007) 110 (11): 749.

https://doi.org/10.1182/blood.V110.11.749.749

Published: 2007

Journal Articles

Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity.

Andy C. Rawstron, PhD, James A.L. Fenton, PhD, Marieth Plummer, MSc, Harry O. King, BSc, Fiona L. Bennett, MSc, Andrew S. Jack, PhD, Peter Hillmen, MD

Blood (2006) 108 (11): 30.

https://doi.org/10.1182/blood.V108.11.30.30

Published: 2006

Journal Articles

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

Sharon L. Barrans, PhD, Kathryn Turner, MSc, Sheila J.M. O’Connor, PhD, Andrew S. Jack, MD, Roger G. Owen, MD

Blood (2006) 108 (11): 4639.

https://doi.org/10.1182/blood.V108.11.4639.4639

Published: 2006

Journal Articles

EBV Related Transformation Events in CLL.

Hazem A. Sayala, MD, Sheila J. O’Connor, PhD, Andrew S. Jack, PhD, Chetan Patalappa, Peter Hillmen, MD, PhD, Roger G. Owen, MD

Blood (2006) 108 (11): 4963.

https://doi.org/10.1182/blood.V108.11.4963.4963

Published: 2006

Journal Articles

Expression of FOXP1 in a Poor Prognostic Sub-Group of DLBCL Is Associated with Deregulated Expression of AID.

James A.L. Fenton, DPhil, Sharon L. Barrans, PhD, Andrew S. Jack, PhD

Blood (2006) 108 (11): 2034.

https://doi.org/10.1182/blood.V108.11.2034.2034

Published: 2006

Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD

Blood (2005) 106 (11): 2936.

https://doi.org/10.1182/blood.V106.11.2936.2936

Published: 2005

Journal Articles

IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.

James A.L. Fenton, DPhil, David Gonzalez, PhD, Andy C. Rawstron, PhD, Gareth J. Morgan, MS, BCh, PhD, Andrew S. Jack, MB ChB PhD, Stephen J. Richards, PhD, Peter Hillmen, MB ChB PhD

Blood (2004) 104 (11): 2793.

https://doi.org/10.1182/blood.V104.11.2793.2793

Published: 2004

NARROW

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression

The Emergence of Clonally Related Hodgkin Lymphoma Following B-Cell Malignancies Treated with Rituximab.

Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease.

Response: Bone marrow involvement and outcome in Burkitt lymphoma and diffuse large B-cell lymphoma

The Pattern of BCL6 Intron 1 Mutations in Healthy Individuals with BCL2;IgH Is Similar to That Seen in Lymphomas

Aberrant Co-Expression of Key Transcription Factors BCL6, IRF4 and FOXP1 Are Frequently Observed in Diffuse Large B-Cell Lymphoma

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCL

Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.

Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity.

Rearrangements of MALT1, IgH, FOXP1 , BCL3 and PAX5 Are Rare Events in Extranodal Marginal Zone Lymphoma in the UK.

EBV Related Transformation Events in CLL.

Expression of FOXP1 in a Poor Prognostic Sub-Group of DLBCL Is Associated with Deregulated Expression of AID.

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only